Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry
Berg, David D. , Barnett, Christopher F. , Kenigsberg, Benjamin B. , Papolos, Alexander , Alviar, Carlos L. , Baird-Zars, Vivian M., Barsness, Gregory W. , Bohula, Erin A. , Brennan, Joseph , Burke, James A. , Cremer, Paul , Daniels, Lori B. , DeFilippis, Andrew P. , Granger, Christopher B. , Hollenberg, Steven M. , Horowitz, James M. , Gladden, James D., Katz, Jason N. , Keeley, Ellen C. , Keller, Norma , Kontos, Michael C. , Lawler, Patrick R. , Menon, Venu , Metkus, Thomas S. , Miller, P. Elliott , Nativi-Nicolau, José , Newby, L. Kristin , Park, Jeong-Gun, Phreaner, Nicholas , Roswell, Robert O. , Schulman, Steven P. , Snell, R. Jeffrey, Solomon, Michael A. , Teuteberg, Jeffrey J. , Tymchak, Wayne , Morrow, David A. , Lawler, Patrick , Solomon, Michael A , Morrow, David A , Granger, Christopher B , Roswell, Robert O , Daniels, Lori B , Bohula, Erin A , Cremer, Paul C , Berg, David , Burke, James A., Carnicelli, Anthony , Chaudhry, Sunit‐Preet , Gerber, Daniel , Park, Jeong‐Gun , Sinha, Shashank S , Diepen, Sean van

Mayo Clinic

Circulation: Heart Failure | November 11, 2019 | Volume: 12 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.119.006635 | PMID 31707801 Get It

Background: Temporary mechanical circulatory support (MCS) devices provide hemodynamic assistance for shock refractory to pharmacological treatment. Most registries have focused on single devices or specific etiologies of shock, limiting data regarding overall practice patterns with temporary MCS in cardiac intensive care units. Methods: The CCCTN (Critical Care Cardiology Trials Network) is a multicenter network of tertiary CICUs in North America. Between September 2017 and September 2018, each center (n=16) contributed a 2-month snapshot of consecutive medical CICU admissions. Results: Of the 270 admissions using temporary MCS, 33% had acute myocardial infarction-related cardiogenic shock (CS), 31% had CS not related to acute myocardial infarction, 11% had mixed shock, and 22% had an indication other than shock. Among all 585 admissions with CS or mixed shock, 34% used temporary MCS during the CICU stay with substantial variation between centers (range: 17%–50%). The most common temporary MCS devices were intraaortic balloon pumps (72%), Impella (17%), and veno-arterial extracorporeal membrane oxygenation (11%), although intraaortic balloon pump use also varied between centers (range: 40%–100%). Patients managed with intraaortic balloon pump versus other forms of MCS (advanced MCS) had lower Sequential Organ Failure Assessment scores and less severe metabolic derangements. Illness severity was similar at high- versus low-MCS utilizing centers and at centers with more advanced MCS use. Conclusions: There is wide variation in the use of temporary MCS among patients with shock in tertiary CICUs. While hospital-level variation in temporary MCS device selection is not explained by differences in illness severity, patient-level variation appears to be related, at least in part, to illness severity.
Pathophysiologic and Prognostic Implications of Right Atrial Hypertension in Adults With Tetralogy of Fallot
Egbe, Alexander C. , Bonnichsen, Crystal R. , Reddy, Yogesh N.V. , Bonnichsen, Crystal, Anderson, Jason H. , Nishimura, Rick , Borlaug, Barry A.

Mayo Clinic

Journal of the American Heart Association | November 8, 2019 | Volume: 8 | Issue: 22 | Pages: No page available

10.1161/jaha.119.014148 | PMID 31701796 Get It

Background Right atrial pressure ( RAP ), a composite metric of right ventricular diastolic function, volume status, and right heart compliance, is a predictor of mortality in patients with heart failure due to acquired heart disease. Because patients with tetralogy of Fallot ( TOF ) might have abnormal right atrial and ventricular mechanics caused by myocardial injury and remodeling, we hypothesized that RAP would be associated with disease severity and cardiovascular adverse events in this population. Methods and Results We performed a cohort study of adults with TOF who underwent right heart catheterization at the Mayo Clinic Rochester between 1990 and 2017. The objective was to determine the association between RAP and multiple domains of disease severity in TOF (percentage of predicted peak oxygen consumption, atrial or ventricular arrhythmia, and heart failure hospitalization), as well as cardiovascular adverse events, defined as sustained ventricular tachycardia, resuscitated or aborted sudden death, heart transplantation, or death. Among 225 patients (113 male; mean age: 39±14 years), mean RAP was 10.7±5.2 mm Hg and median was 10 mm Hg (interquartile range: 7–13 mm Hg). Increasing RAP was associated with atrial or ventricular arrhythmias (odds ratio: 5.01; 95% CI, 1.22–23.49; P <0.001), heart failure hospitalization (odds ratio: 1.47; 95% CI, 1.10–2.39; P =0.033) per 5 mm Hg, and worsening exercise capacity (peak oxygen consumption; R 2 =0.74, r =−0.86, P <0.001). RAP was a predictor of cardiovascular adverse events (hazard ratio: 1.28; 95% CI, 1.10–1.47; P =0.028) per 5 mm Hg. Conclusions In symptomatic patients with TOF , increasing RAP correlates with multiple domains of disease severity (risk stratification) and predicts future cardiovascular events (prognostication). These data have potential clinical implications in the target population of symptomatic TOF patients.
Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry
Jurisic, Stjepan , Gili, Sebastiano , Cammann, Victoria L. , Kato, Ken , Szawan, Konrad A. , Bossone, Eduardo , Citro, Rodolfo , Sarcon, Annahita, Napp, L. Christian , Franke, Jennifer , Knorr, Maike, Heiner, Susanne, Burgdorf, Christof , Köenig, Wolfgang , Pott, Alexander , Kherad, Behrouz , Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Meyer, Philippe , Arroja, José David , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Fischer, Thomas, Vasankari, Tuija , Airaksinen, Juhani , Dworakowski, Rafał , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Kozel, Martin , Winchester, David E. , Gilyarova, Ekaterina, Gilyarov, Mikhail , El‐Battrawy, Ibrahim , Akın, İbrahim , Ukena, Christian , Poglajen, Gregor , Paolini, Carla , Bilato, Claudio , Carrilho‐Ferreira, Pedro , Pinto, Fausto J. , Opolski, Grzegorz , MacCarthy, Philip , Kobayashi, Yoshio , Prasad, Abhiram , Rihal, Charanjit S. , Widimský, Petr , Tschöpe, Carsten , Pieske, Burkert , Rottbauer, Wolfgang , Felix, Stephan B. , Borggrefe, Martin , Katus, Hugo A. , Münzel, Thomas , Böhm, Michael , Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Gilyarov, Mikhail , Bossone, Eduardo , Citro, Rodolfo , El-Battrawy, Ibrahim , Prasad, Abhiram , Tschöpe, Carsten , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Kobza, Richard , Gilyarov, Mikhail , Ukena, Christian , Bilato, Claudio , D’Ascenzo, Fabrizio , Jaguszewski, Miłosz , Noutsias, Michel , Kaiser, Christoph A. , Dichtl, Wolfgang , Delmas, Clément , Lairez, Olivier , Toušek, Petr , Shilova, Alexandra S. , Gałuszka, Jan , Rihal, Charanjit S. , Horowitz, John D. , Mario, Carlo Di , Crea, Filippo , Hasenfuß, Gerd , Braun-Dullaeus, Ruediger Christian , Thiele, Hölger , Bauersachs, Johann , Schunkert, Heribert , Bax, Jeroen J. , Ruschitzka, Frank T.

Mayo Clinic

Journal of the American Heart Association | November 1, 2019 | Volume: 8 | Issue: 21 | Pages: No page available

10.1161/jaha.118.011194 | PMID 31672100 Get It

Background Left ventricular ( LV ) recovery in takotsubo syndrome ( TTS ) occurs over a wide‐ranging interval, varying from hours to weeks. We sought to investigate the clinical predictors and prognostic impact of recovery time for TTS patients. Methods and Results TTS patients from the International Takotsubo Registry were included in this study. Cut‐off for early LV recovery was determined to be 10 days after the acute event. Multivariable logistic regression was used to assess factors associated with the absence of early recovery. In‐hospital outcomes and 1‐year mortality were compared for patients with versus without early recovery. We analyzed 406 patients with comprehensive and serial imaging data regarding time to recovery. Of these, 191 (47.0%) had early LV recovery and 215 (53.0%) demonstrated late LV improvement. Patients without early recovery were more often male (12.6% versus 5.2%; P =0.011) and presented more frequently with typical TTS (76.3% versus 67.0%, P =0.040). Cardiac and inflammatory markers were higher in patients without early recovery than in those with early recovery. Patients without early recovery showed unfavorable 1‐year outcome compared with patients with early recovery ( P =0.003). On multiple logistic regression, male sex, LV ejection fraction <45%, and acute neurologic disorders were associated with the absence of early recovery. Conclusions TTS patients without early LV recovery have different clinical characteristics and less favorable 1‐year outcome compared with patients with early recovery. The factors associated with the absence of early recovery included male sex, reduced LV ejection fraction, and acute neurologic events. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01947621.
Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis
Gelbard, Alexander , Anderson, Catherine , Berry, Lynne D. , Amin, Milan R. , Benninger, Michael S. , Blumin, Joel H. , Bryson, Paul C. , Castellanos, Paul F., Chen, Sheau‐Chiann , Cohen, Seth M. , Crawley, Brianna K. , Dailey, Seth H. , Daniero, James J. , Alarcón, Alessandro de , Donovan, Donald T., Edell, Eric S. , Ekbom, Dale C. , Fernandes‐Taylor, Sara , Fink, Daniel S. , Franco, Ramon A. , Garrett, C. Gaelyn , Guardiani, Elizabeth , Hoffman, Henry T. , Hogikyan, Norman D. , Howell, Rebecca J. , Huang, Li‐Ching , Hussain, Lena K., Johns, Michael M. , Kasperbauer, Jan L. , Khosla, Sid , Kinnard, Cheryl, Kupfer, Robbi A. , Langerman, Alexander , Lentz, Robert J. , Lorenz, Robert R. , Lowery, Anne S. , Makani, Samir, Maldonado, Fabien , Mannion, Kyle , Matrka, Laura , McWhorter, Andrew J., Meratı, Albert L., Mori, Matthew , Netterville, James L. , O’Dell, Karla , Ongkasuwan, Julina , Postma, Gregory N. , Reder, Lindsay , Rohde, Sarah L. , Richardson, Brent E. , Rickman, Otis B. , Rosen, Clark A. , Rutter, Michael J. , Sandhu, Guri, Schindler, Joshua S. , Schneider, Glenn Todd , Shah, Rupali N., Sikora, Andrew G. , Sinard, Robert J. , Smith, Marshall E. , Smith, Libby J. , Soliman, Ahmed M. S. , Sveinsdóttir, Sigríður, Daele, Douglas J. Van , Veivers, David , Verma, Sunil P., Weissbrod, Philip A. , Wootten, Christopher T. , Shyr, Yu , Francis, David O. , Chen, Sheau-Chiann , Ongkasuwan, Julian , Cohen, Seth M , Hoffman, Henry T , Richardson, Brent E , Gelbard, Alexander , Weissbrod, Philip A , Bock, Jonathan M. , Clary, Matthew S. , Hillel, Alexander T. , Lott, David G. , Weinberger, Paul , Amin, Milan R

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 31, 2019 | Volume: 146 | Issue: 1 | Pages: 20

10.1001/jamaoto.2019.3022 | PMID 31670805 Get It

Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
Gralow, Julie R. , Barlow, William E. , Paterson, Alexander , Lew, Danika L., Stopeck, Alison , Hayes, Daniel F. , Hershman, Dawn L. , Schubert, Mark M., Clemons, Mark , Poznak, Catherine Van , Dees, Elizabeth Claire , Messino, Michael J., Margolis, Jeffrey, Dakhil, Shaker R. , Chew, Helen K. , Dammann, Kim Z, Abrams, Jeffrey S. , Livingston, Robert B., Ingle, James N. , Hershman, Dawn L , Gralow, Julie R , Barlow, William E , Miao, Jieling , Falkson, Carla I. , Elias, Anthony , Hortobágyi, Gabriel N.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 28, 2019 | Volume: 112 | Issue: 7 | Pages: 698-707

10.1093/jnci/djz215 | PMID 31693129 Get It

Abstract Background Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates in postmenopausal patients. SWOG/Alliance/Canadian Cancer Trials Group/ECOG-ACRIN/NRG Oncology study S0307 compared the efficacy of three bisphosphonates in early-stage breast cancer. Methods Patients with stage I–III breast cancer were randomly assigned to 3 years of intravenous zoledronic acid, oral clodronate, or oral ibandronate. The primary endpoint was disease-free survival (DFS) with overall survival as a secondary outcome. All statistical tests were two-sided. Results A total of 6097 patients enrolled. Median age was 52.7 years. Prior to being randomly assigned, 73.2% patients indicated preference for oral vs intravenous formulation. DFS did not differ across arms in a log-rank test (P = .49); 5-year DFS was 88.3% (zoledronic acid: 95% confidence interval [CI] = 86.9% to 89.6%), 87.6% (clodronate: 95% CI = 86.1% to 88.9%), and 87.4% (ibandronate: 95% CI = 85.6% to 88.9%). Additionally, 5-year overall survival did not differ between arms (log rank P = .50) and was 92.6% (zoledronic acid: 95% CI = 91.4% to 93.6%), 92.4% (clodronate: 95% CI = 91.2% to 93.5%), and 92.9% (ibandronate: 95% CI = 91.5% to 94.1%). Bone as first site of recurrence did not differ between arms (P = .93). Analyses based on age and tumor subtypes showed no treatment differences. Grade 3/4 toxicity was 8.8% (zoledronic acid), 8.3% (clodronate), and 10.5% (ibandronate). Osteonecrosis of the jaw was highest for zoledronic acid (1.26%) compared with clodronate (0.36%) and ibandronate (0.77%). Conclusions We found no evidence of differences in efficacy by type of bisphosphonate, either in overall analysis or subgroups. Despite an increased rate of osteonecrosis of the jaw with zoledronic acid, overall toxicity grade differed little across arms. Given that patients expressed preference for oral formulation, efforts to make oral agents available in the United States should be considered.
A decreased abundance of clostridia characterizes the gut microbiota in eosinophilic esophagitis
Kashyap, Purna , Johnson, Stephen , Geno, Debra M., Lekatz, Heather, Lavey, Crystal, Alexander, Jeffrey A. , Katzka, David A. , Lekatz, Heather R, Katzka, D A , Chen, Jun

Mayo Clinic

Physiological Reports | October 25, 2019 | Volume: 7 | Issue: 20 | Pages: No page available

10.14814/phy2.14261 | PMID 31650712 Get It

148. Retrospective Evaluation of Acute Cholangitis and Clinical Implication and Management of Secondary Bacteremia
Hamdi, Ahmed , Miller, Alexander T. , Diaz, Mark Anthony , Yetmar, Zachary A. , Fida, Madiha , Beam, Elena

Mayo Clinic

Open Forum Infectious Diseases | October 23, 2019 | Volume: 6 | Issue: Supplement_2 | Pages: S101-S101

10.1093/ofid/ofz360.223 Get It

Abstract Background Optimum duration of antimicrobial therapy for acute bacteremic cholangitis is not well established; however, 4–7 days is recommended by the 2018 Tokyo guidelines in those without Gram-positive bacteremia. Methods A retrospective study performed at Mayo Clinic - Rochester, Florida and Arizona sites was conducted, reviewing all adult patients with the first episode of acute cholangitis secondary to biliary stone obstruction, between January 1, 2012 and December 31, 2017. We reviewed the duration of prescribed antimicrobials. Results Among 331 included cases, 197(60%) were men, 66 (20%) were immuno-compromised. Presenting symptoms included fever in 202 (61.5%), abdominal pain in 289 (87%), jaundice 128(38.7%), and altered mentation in 49 (15%). Among these, 256 (77%) were classified as “definite” and 38 (11.5%) were “suspected” using the 2018 Tokyo guideline classification. Cholangitis grade was grade III in 134 (40.5%); grade II in 115 (34.7%); and grade I in 82 (24.8%). Majority of cases, 321 (97%), underwent source control—most commonly 309 (96%) achieved by endoscopic retrograde cholangiopancreatography (ERCP). Source control occurred within 24 hr of presentation in 197 (61.4%) of the cases. Bacteremia was documented in 131/277 (47%). Majority of bacteremias were due to Gram-negative organisms in 119 (91%). Mean duration of antibiotic therapy following “source control” was 9.6 days (SD 7.0). Cases with bacteremia, resulted in longer treatment duration, mean of 13 days (SD 5.6), regardless of the isolated organism. Overall 30 day mortality was 14/331 (4.2%). No mortality difference was noted in patients who underwent early (within 12 hours) vs. later source control (4.55% Vs. 4.53%), nor in those who received more or less than 6 days of antibiotic therapy after source control (4.7% Vs. 3.9%, P = 0.76). No difference in mortality was observed in those with or without bacteremia. Conclusion Our results note the use of longer courses of antimicrobials for management of bacteremic cholangitis, regardless of the organism type. This population could be a prime target for an antimicrobial stewardship intervention, to decrease the duration of prescribed antimicrobials in accordance with recent guidelines. Disclosures All authors: No reported disclosures.
Mild Coarctation of Aorta is an Independent Risk Factor for Exercise-Induced Hypertension
Egbe, Alexander C. , Allison, Thomas G. , Ammash, Naser M.

Mayo Clinic

Hypertension | October 21, 2019 | Volume: 74 | Issue: 6 | Pages: 1484-1489

10.1161/hypertensionaha.119.13726 | PMID 31630577 Get It

Exercise-induced hypertension is a predictor of cardiovascular events in patients with coarctation of aorta (COA). However, it is unclear whether mild COA diagnosis is an independent risk factor of exercise-induced hypertension. We hypothesized that for every unit increase in exercise, patients with COA (without hemodynamically significant coarctation) will have a higher rise in systolic blood pressure (SBP) compared with matched controls. One hundred forty-nine patients with COA (aortic coarctation peak velocity <2 m/s) who underwent exercise testing were matched 1:1 to controls using propensity score method based on age, sex, body mass index, hypertension diagnosis, and SBP at rest. We compared exercise-induced change in SBP between patients with COA and controls and also assessed the correlation between Doppler-derived aortic vascular function indices (effective arterial elastance index and total arterial compliance index) and exercise-induced changes in SBP. Compared with controls, patients with COA had a greater change in SBP per unit metabolic equivalent (β=2.86; 95% CI, 1.96–4.77 versus 1.07, 95% CI, −0.15 to 1.75; P =0.018) and per unit oxygen pulse (β=4.57; 95% CI, 2.97–7.12 versus 1.45, 95% CI, −0.79 to 2.09, P <0.001). There was a correlation between SBP peak −SBP rest and elastance index ( r =0.38, P =0.032) and between SBP peak −SBP rest and total arterial compliance index ( r =−0.51, P =0.001), suggesting an association between vascular dysfunction and exercise-induced BP changes. Patients with COA, without significant obstruction, had higher exercise-induced changes in SBP after adjustment for other risk factors for hypertension. Considering the already known prognostic importance of exercise-induced hypertension, the current study highlights the potential role of exercise testing for risk stratification of patients with mild COA.
P323Haemodynamic implications of mitral regurgitation in heart failure with preserved ejection fraction
Delpon, M A Tamargo, Masaru, O, Egbe, Alexander C. , Reddy, Yogesh N.V. , Pislaru, Sorin V. , Borlaug, Barry A.

Mayo Clinic

European Heart Journal | October 21, 2019 | Volume: 40 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehz747.0158 Get It

Abstract Background Mild to moderate mitral regurgitation (MR) is a common finding in heart failure with preserved ejection fraction (HFpEF). MR is often considered to be an innocent bystander, yet little data is available regarding its implications. Aim Determine the pathophysiologic correlates of MR in HFpEF Methods We retrospectively studied 280 patients with invasively proven HFpEF. MR was absent (None or trivial) in 163 subjects (Non-MR-HFpEF), and present in 117 (MR-HFpEF; 78 mild and 39 moderate MR). 247 subjects also underwent invasive cardiopulmonary exercise testing. Results At rest, MR-HFpEF subjects displayed higher pulmonary artery pressures (PAP), PCWP, and pulmonary vascular resistance (PVR; Table). During exercise, PAP and PCWP were not significantly different among groups, but MR-HFpEF displayed reduced ability to enhance cardiac output (CO) in response to heightened metabolic demand (oxygen consumption, VO2; Figure). Baseline characteristics and haemodynamic characterization at baseline and peak exercise Baseline characteristics Non-MR-HFpEF (N=163) MR-HFpEF (N=117) p value Age 66±11 71±10 0.0002 Female (%) 56 69 0.02 AFib (%) 13 38 <0.0001 Nt proBNP 192 [66, 557] 870 [401, 2135] <0.0001 E/E' 12.3±5.5 15.6±7.2 0.0006 LVEF (%) 64±6 62±6 0.0001 RV fractional area change (%) 51±9 47±10 0.0001 Mean PA (mmHg) 25±7 28±9 0.001 Mean PCWP (mmHg) 15±5 17±6 0.0002 PVR (Woods) 2.0±1.1 2.5±1.4 0.015 CO (L/min) 5.5±1.6 4.8±1.3 0.12 Peak exercise hemodynamics Non-MR-HFpEF (N=152) MR-HFpEF (N=95) p value Mean PA (mmHg 45±10 46.5±10 0.07 Mean PCWP (mmHg) 32±6 31±6 0.6 PVR (Woods) 1.8±1.6 2.7±2.4 0.002 CO (L/min) 9.1±3 7.2±3 0.01 P value adjusted for age, gender and BMI. CO change in response to VO2 increase Conclusion The presence of even mild MR in HFpEF is associated with more adverse hemodynamics, greater pulmonary vascular dysfunction and impaired CO reserve with exercise. Further study is required to better understand the natural history and treatment for MR in HFpEF. Acknowledgement/Funding None
Effects of Peptide YY on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men
Izzi‐Engbeaya, Chioma , Jones, Sophie , Crustna, Yoshibye, Machenahalli, Pratibha, Papadopoulou, Deborah , Panayi, Christos, Starikova, Jessica , Eng, Pei Chia , Mills, Edouard , Yang, Lisa, Ratnasabapathy, Risheka , Sykes, Mark, Plumptre, Isabella , Coumbe, Ben, Wing, Victoria C., Pacuszka, Ewa, Bech, Paul, Tharakan, George, Tan, Tricia , Veldhuis, Johannes D. , Abbara, Ali , Comninos, Alexander , Dhillo, Waljit S. , Veldhuis, Johannes, Modi, Manish , Phylactou, Maria , MINNION, JAMES S.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 19, 2019 | Volume: 105 | Issue: 3 | Pages: 833-838

10.1210/clinem/dgz103 | PMID 31628465 Get It

Abstract Context Central and peripheral administration of peptide YY (PYY) has potent anorectic effects, and PYY analogs are under development as antiobesity treatments. Recent animal data suggest PYY may also influence the reproductive axis; however the effects of PYY on the human reproductive system are unknown. Objective To investigate the effects of PYY administration on the reproductive axis in healthy young men. Design Single-blind, randomized, placebo-controlled crossover study. Setting Clinical Research Facility, Imperial College Healthcare NHS Trust. Participants Eighteen healthy eugonadal men (mean age 24.1 ± 0.9 years, mean body mass index 22.2 ± 0.4 kg/m2). Intervention Eight-hour intravenous infusion of 0.4 pmol/kg/min PYY3-36 or rate-matched vehicle infusion. Main Outcome Measures Number of luteinizing hormone (LH) pulses, LH, follicle stimulating hormone (FSH), and testosterone levels. Results The number of LH pulses (mean number of LH pulses/8 hours: PYY 4.4 ± 0.3 vs vehicle 4.4 ± 0.4, P &gt; .99), LH area under the curve (AUC) (PYY 1503 ± 79 IU.min/L vs vehicle 1574 ± 86 IU.min/L, P = .36), FSH AUC (PYY 1158 ± 513 IU.min/L vs vehicle 1199 ± 476 IU.min/L, P = .49) and testosterone AUC (PYY 10 485 ± 684 IU.min/L vs vehicle 11 133 ± 803 IU.min/L, P = .24) were similar during PYY and vehicle infusions. Conclusions Acute intravenous infusion of 0.4 pmol/kg/min PYY does not affect the reproductive axis in healthy men.